Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Alcohol in pharmaceutical products

G E Dukes, J G Kuhn, R P Evens

American Family Physician

|September 1, 1977

Summary

This summary is machine-generated.

Many pharmaceutical products contain high alcohol concentrations, posing risks for patients undergoing specific therapies or with certain medical conditions. This hidden alcohol content complicates patient management and abstinence programs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans.

Neurogastroenterology and motility·2017

Same author

Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.

Haemophilia : the official journal of the World Federation of Hemophilia·2017

Same author

Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?

Haemophilia : the official journal of the World Federation of Hemophilia·2015

Same author

The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial.

Neurogastroenterology and motility·2015

Same author

Drugs acting at 5-HT4 , D2 , motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach.

Neurogastroenterology and motility·2014

Same author

The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success.

Clinical pharmacology and therapeutics·2014

Area of Science:

Pharmacology
Patient Management

Background:

Alcohol is a common diluent in over 500 pharmaceutical products, with concentrations reaching up to 68%.
The presence of alcohol in medications can lead to significant patient management challenges.

Purpose of the Study:

To highlight the potential risks and complications associated with alcohol content in pharmaceutical products.
To inform healthcare providers about the implications for patient care, particularly for vulnerable populations.

Main Methods:

Review of pharmaceutical product formulations to identify alcohol content.
Analysis of patient cases and medical conditions where alcohol in medications poses a risk.

Main Results:

Over 500 proprietary products contain alcohol as a diluent, some at high concentrations (up to 68%).

Related Experiment Videos

Specific patient groups, including those on disulfiram therapy, with peptic ulcers, or on CNS depressants, face increased risks.

Alcohol content complicates abstinence programs and poses challenges in addressing adolescent alcohol abuse.

Conclusions:

The significant alcohol content in numerous pharmaceuticals necessitates careful consideration in patient management.
Healthcare professionals must be aware of these risks to ensure patient safety and effective treatment.
Further attention is needed regarding the impact of pharmaceutical alcohol on addiction and abuse programs.